

Open-Source Clinical Decision Support Models

December 2, 2011

NHGRI Workshop on Characterizing and Displaying Genetic Variants for Clinical Action, Gaithersburg, Maryland

Kensaku Kawamoto, MD, PhD

Director, Knowledge Management and Mobilization
Assistant Professor, Department of Biomedical Informatics
University of Utah
kensaku.kawamoto@utah.edu



UNIVERSITY OF UTAH
HEALTH CARE

Disclosures

- I am or have recently been a consultant to Partners HealthCare, Inflexxion, and RAND Corporation.
- I was formerly a consultant for Religent, Inc. and formerly a co-owner and consultant for Clinica Software, Inc.
- I have no financial competing interests related to OpenCDS.



Presentation Objectives

- Describe clinical decision support (CDS) and how it could help bridge the translation gap for personalized medicine
- Identify requirements for scaling CDS for personalized medicine (PM) on a national scale
- Describe an open-source, standards-based CDS platform (OpenCDS) that could enable CDS for PM at scale



Clinical Decision Support (CDS)

- Definition
 - The provision of **pertinent knowledge and/or person-specific information** to clinical decision makers to enhance health and health care (Osheroff et al., *JAMIA*, 2006)
- Supports translation of **evidence into practice**
 - CDS systems that provide patient-specific care recommendations automatically and within clinical workflows have significantly improved care quality in >90% of RCTs (Kawamoto et al., *BMJ*, 2005)



CDS Example: Disease Mgmt. Dashboard

https://clinapp6.duhs.duke.edu:8081 - Patient Summary for [REDACTED] - Microsoft Internet Explorer

Allergies/ADE Problems Medications Medications From Notes Vitals Cautions Disease Mgmt. Print ? Send Feedback Close

All Health Maintenance **Diabetes*** Hypertension*

Re-Evaluate Input Observations Last evaluated Mon Jan 12 21:09:31 EST 2009

Diabetes Remove from Diabetes List

Focus	Status	Relevant Data	Last Done	Guidelines
Height	Not Due	Height: 154.9cm (61.0in)	12/15/08(age 61y 3m)	21+yo: once after age 21
Weight/BMI	DUE NOW	Weight: 77.1kg (170.0lb) BMI: 32.1	01/08/09 (0m 4d ago)	21+yo: q visit. Goal: BMI <25
B.P.	DUE NOW	BP: 120/69 mm Hg <i>Patient has diabetes or GFR <60</i>	01/08/09 (0m 4d ago)	18+yo: annual; if diabetic or HTN q visit. Goal <140/90, 130/80 if diabetic or GFR <60.
Alcohol Screen	Not Due	Abstains	01/08/09 (0m 4d ago)	10+yo: check alcohol use yearly (excessive: males >2/d, females >1/d)
Visual Foot Exam	DUE NOW		01/08/09 (0m 4d ago)	q visit
Foot Monofilament	Not Due		01/08/09 (0m 4d ago)	annual
HgbA1C	Not Due	HgbA1C: 6.2%	01/08/09 (0m 4d ago)	21+yo: q6mo if <7%, q3mo if ≥ 7%. Goal: <7%.
Urine Micro alb/cr	Not Due	alb/cr ratio: * mg/g	10/08/08 (3m 4d ago)	10+yo: annual
Total Chol.	Not Due	Total-C: 151 mg/dL	12/15/08 (0m 28d ago)	annual, goal <200
LDL Chol.	Not Due	LDL-C: 94 mg/dL	12/15/08 (0m 28d ago)	annual, goal <100
Eye Exam	DUE NOW	<i>Intervention considered but not delivered on 01/08/09. Reason: Scheduled</i>		10+yo: annual
Flu Vacc.	CONSIDER		>2y ago	annual, unless egg allergic
Pneum. Vacc.	Not due		01/01/06 (3y 0m ago)	once; revacc if ≥65 and last 5+ yrs ago when <65
ASA (81 mg)	Not Due	Not known to be allergic to aspirin Aspirin listed as prescribed		40+yo: no contraindications
Education	Not Due	Completed	01/08/09 (0m 4d ago)	once; repeat annually if HgbA1C ≥7%



Potential CDS Applications Areas for PM

- Test ordering
 - Recommend indicated test
 - Recommend against test with dubious clinical utility
- Personalized test interpretation
 - Combine genetic test result with clinical data to provide personalized risk assessment and care guidance
- Family history analysis
 - Tailor preventive care guidance based on family history
- Therapy
 - Provide genetically-informed drug therapy guidance



CDS Example: Warfarin PGx Dosing

Baseline INR: <input type="text" value="1.2"/>	Current Smoker: <input type="radio"/> Yes <input checked="" type="radio"/> No	Liver Disease: <input type="radio"/> Yes <input checked="" type="radio"/> No	Current or recent NPO: <input type="radio"/> Yes <input checked="" type="radio"/> No	Estimated blood loss from recent surgery: <input type="text" value="0"/> mL	Calculated body surface area: <input type="text" value="1.492"/> m ²			
On Direct Thrombin Inhibitor (e.g., hirudin, bivalirudin): <input type="radio"/> Yes <input checked="" type="radio"/> No	Statin use: <input type="text" value="Pravastatin/Pravachol®"/>	Amiodarone use: <input type="text" value="0"/> mg/day	On Azole Antifungal (e.g., ketoconazole, fluconazole): <input type="radio"/> Yes <input checked="" type="radio"/> No	On Metronidazole: <input type="radio"/> Yes <input checked="" type="radio"/> No	On Rifampin: <input type="radio"/> Yes <input checked="" type="radio"/> No			
On Carbamazepine: <input type="radio"/> Yes <input checked="" type="radio"/> No	On Propafenone: <input type="radio"/> Yes <input checked="" type="radio"/> No	On Steroid: <input type="radio"/> Yes <input checked="" type="radio"/> No	On Fluoroquinolone (e.g., moxifloxacin, ciprofloxacin): <input type="radio"/> Yes <input checked="" type="radio"/> No	On Phenytoin (e.g., Dilantin): <input type="radio"/> Yes <input checked="" type="radio"/> No	On Sulfonamide: <input type="radio"/> Yes <input checked="" type="radio"/> No			
CYP2C9 genotype: <input type="text" value="*2/*3"/>	VKORC1-1639/3673 genotype: <input type="text" value="AA"/>							
Prior Doses and Recent Labs:								
Prior doses (past week):	7/13 (Tue)	7/14 (Wed)	7/15 (Thu)	7/16 (Fri)	7/17 (Sat)	7/18 (Sun)	7/19 (Mon)	Most Recent Labs
<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	PTT 37 07/20/2010 13:56:33
Unless manually entered, above doses do not reflect held doses or outside doses. Edit as needed to ensure validity of dosing guidance provided below.								INR 1.5 07/20/2010 13:56:33
								Platelets 180 07/20/2010 13:56:33
								Hemoglobin 14.9 07/20/2010 13:56:33
								Hematocrit 0.42 07/20/2010 13:56:33
Warfarin Order								
Dosing								
Dosing Guidance: Dosing guidance received from http://www.warfarindosing.org :								
Consider following dosing:								
- dose 1: 2.9 mg/day								
- dose 2: 1.6 mg/day								
- dose 3: 1.6 mg/day								
<input type="radio"/> Consistent:	<input type="text"/> mg PO QHS x <input type="text" value="3"/> day(s)							
<input type="radio"/> Custom QHS:	7/20 (Tue)	7/21 (Wed)	7/22 (Thu)	7/23 (Fri)	7/24 (Sat)	7/25 (Sun)	7/26 (Mon)	
	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	



Achilles' Heel of CDS: Limited Scalability

- Despite demonstrated effectiveness, CDS is not widely available
 - Most CDS capabilities only work within specific institutions and health IT systems
- We are still trying to scale up “traditional” CDS capabilities that have been validated for decades
 - Unless we focus on scalability, CDS will have a limited impact on PM for decades to come



The NEW ENGLAND JOURNAL of MEDICINE

Protocol-Based Computer Reminders, the Quality of Care and
the Non-Perfectibility of Man

Clement J. McDonald, M.D.

N Engl J Med 1976; 295:1351-1355 |

December 9, 1976

What is Needed to Scale CDS for PM?

- Standardized representation of relevant **patient data**
- Centrally managed repositories of high-quality, computer-processable medical **knowledge**
- Standard approaches for **leveraging** the encoded knowledge to provide patient-specific advice

Kawamoto K, Lobach DF, Willard HF, Ginsburg GS. A national CDS infrastructure to enable the widespread and consistent practice of genomic and personalized medicine. *BMC Medical Informatics and Decision Making*, 2009, 9:17.



OpenCDS

- An **open-source, standards-based** CDS platform designed to enable CDS at scale
- Addresses core requirements of a national CDS infrastructure for PM
 - Uses standard data models
 - Can leverage various knowledge resources, both externally and internally developed
 - Provides a standard approach for EHR systems to leverage CDS resources over the Internet to obtain patient-specific advice



Collaborators

- University of Utah
- HP Advanced Federal Healthcare Innovation Lab
- HLN Consulting, LLC
- Apelon, Inc.
- Intermountain Healthcare
- New York Citywide Immunization Registry
- Alabama Department of Public Health
- Veterans Health Administration
- Wolters Kluwer Health
- EBSCO
- Univ. of NC at Chapel Hill
- Main Line Health
- Hospital Universitario Virgen del Rocío, Spain
- Keona Health
- Mass. General Hospital
- Stanford University
- MaRS Innovation, Canada
- SmartCare, Africa
- Emetra AS, Norway
- Visumpoint, LLC
- Genesys, LLC
- df8health
- IsoDynamic, Inc.
- Calcudos.com, Inc.
- CogniTech Corporation



Patient Activity Rounding Orders OR Summary ESIG Help All Results -Choose Patient List-

Duke type MRN Summary: DM | No Known Drug Allergies

All Results Dictated Reports Procs/Ops Radiology General Labs Microbiology Pathology Resp. Care New Res

Report Type	Date/Time	Status	Fac
Comprehensive Clinic Note	07/06/2007 00:00		DUMI
GLYCATED HEMOGLOBIN (HBA1C)	03/22/2007 15:01		DUMI
CHOLESTEROL, TOTAL	03/22/2007 15:01		DUMI
LDL-CHOLESTEROL (DIRECT)	03/22/2007 15:00		DUMI
FAM Endocrinology Follow Up	03/22/2007 00:00		DUMI
MICROALBUMIN/CREATININE RATIO	07/13/2006 16:54		DUMI
GLYCATED HEMOGLOBIN (HBA1C)	07/13/2006 16:49		DUMI
LIPID PANEL (CALCULATED LDL)	07/13/2006 16:49		DUMI
OP4 (TBILI,AST,ALPHOS,ALT)	07/13/2006 16:49		DUMI
OP7 (CO2,CL,K,NA,BUN,GLU,CR)	07/13/2006 16:49		DUMI
Endocrinology Consultation	07/13/2006 00:00		DUMI
MAMMOGRAPHY-SCREENING EXAM	05/25/2005 11:55		DUMI
Clinic Note	05/25/2005 00:00	Preliminary	DUMI
MAMMOGRAPHY-SCREENING EXAM	05/19/2004 09:00		DUMI

Patient: [REDACTED]

GENLAB Chemistry: Final 03/22/2007 15:01 Acc# [REDACTED]

GLYCATED HEMOGLOBIN (HBA1C)

GLYCATED HEMOGLOBIN (HBA1C) +8.3
AVERAGE BLOOD GLUCOSE (CALC) 197

INTERPRETIVE DATA

AVERAGE BLOOD GLUCOSE ASSOCIATED WITH
HEMOGLOBIN (BASED ON DCCT)

Pneum. Vacc.	M	01/01/06 (3y 0m ago)	once; revacc if >=65 and last 5+ yrs ago when <65
ASA (81 mg)	M	known to be allergic to aspirin aspirin listed as prescribed	40+yo: no contraindications

Care Advice

Pt data

OpenCDS Care Guidance Service

EHR System

Patient Data Sources



> [Warfarin Dosing](#)

> [Clinical Trial](#)

> [Outcomes](#)

> [Hemorrhage Risk](#)

> [Patient Education](#)

> [Contact Us](#)

> [References](#)

> [Glossary](#)

> [About Us](#)

User:
Patient:
[Version 2.34](#)
Build : Oct 30, 2011

Required Patient Information

Age: Sex: Ethnicity:

Race:

Weight: lbs or kgs

Height: (feet and inches) or (cms)

Smokes: Liver Disease:

Indication:

Baseline INR: Target INR: Randomize & Blind

Amiodarone/Cordarone® Dose: mg/day

Statin/HMG CoA Reductase Inhibitor:

Any azole (eg. Fluconazole):

Sulfamethoxazole/Septtra/Bactrim/Cotrim/Sulfatrim:

Genetic Information

[VKORC1-1639/3673](#):

[CYP4F2 V433M](#):

[GGCX rs11676382](#):

[CYP2C9*2](#):

[CYP2C9*3](#):

[CYP2C9*5](#):

[CYP2C9*6](#):

[Accept Terms of Use](#)

> ESTIMATE WARFARIN DOSE

WarfarinDosing.org Integration via OpenCDS

Baseline INR: <input type="text" value="1.2"/>	<u>Current Smoker:</u> <input type="radio"/> Yes <input checked="" type="radio"/> No	<u>Liver Disease:</u> <input type="radio"/> Yes <input checked="" type="radio"/> No	Current or recent NPO: <input type="radio"/> Yes <input checked="" type="radio"/> No	Estimated blood loss from recent surgery: <input type="text" value="0"/> mL	<u>Calculated body surface area:</u> <input type="text" value="1.492"/> m ²			
On Direct Thrombin Inhibitor (e.g., hirudin, bivalirudin): <input type="radio"/> Yes <input checked="" type="radio"/> No	<u>Statin</u> use: <input type="text" value="Pravastatin/Pravachol®"/>	Amiodarone use: <input type="text" value="0"/> mg/day	On Azole Antifungal (e.g., ketoconazole, fluconazole): <input type="radio"/> Yes <input checked="" type="radio"/> No	On Metronidazole : <input type="radio"/> Yes <input checked="" type="radio"/> No	On Rifampin : <input type="radio"/> Yes <input checked="" type="radio"/> No			
On Carbamazepine : <input type="radio"/> Yes <input checked="" type="radio"/> No	On Propafenone : <input type="radio"/> Yes <input checked="" type="radio"/> No	On Steroid : <input type="radio"/> Yes <input checked="" type="radio"/> No	On Fluoroquinolone (e.g., moxifloxacin, ciprofloxacin): <input type="radio"/> Yes <input checked="" type="radio"/> No	On Phenytoin (e.g., Dilantin): <input type="radio"/> Yes <input checked="" type="radio"/> No	On Sulfonamide : <input type="radio"/> Yes <input checked="" type="radio"/> No			
<u>CYP2C9 genotype:</u> <input type="text" value="*2/*3"/>	<u>VKORC1-1639/3673 genotype:</u> <input type="text" value="AA"/>							
Prior Doses and Recent Labs:								
Prior doses (past week):	7/13 (Tue)	7/14 (Wed)	7/15 (Thu)	7/16 (Fri)	7/17 (Sat)	7/18 (Sun)	7/19 (Mon)	Most Recent Labs
<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	PTT 37 07/20/2010 13:56:33
Unless manually entered, above doses do not reflect held doses or outside doses. Edit as needed to ensure validity of dosing guidance provided below.								INR 1.5 07/20/2010 13:56:33
								Platelets 180 07/20/2010 13:56:33
								Hemoglobin 14.9 07/20/2010 13:56:33
								Hematocrit 0.42 07/20/2010 13:56:33
Warfarin Order								
Dosing								
Dosing Guidance: Dosing guidance received from http://www.warfarindosing.org :								
Consider following dosing:								
- dose 1: 2.9 mg/day								
- dose 2: 1.6 mg/day								
- dose 3: 1.6 mg/day								
<input type="radio"/> Consistent:	<input type="text"/> mg PO QHS x <input type="text" value="3"/> day(s)							
<input type="radio"/> Custom QHS:	7/20 (Tue)	7/21 (Wed)	7/22 (Thu)	7/23 (Fri)	7/24 (Sat)	7/25 (Sun)	7/26 (Mon)	
	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	<input type="text"/> mg	



Web-based Authoring – Decision Rules

Find Business rule asset DenomCriteriaM

Save changes Save and close Select Working Sets Val

WHEN

1. Initialize - Note that all criteria below must be met for the rule to fire.
2. Pt.Age.Low - Patient age is greater than or equal to years
3. Pt.Age.High - Patient age is less than or equal to years
4. Pt.Gender - Patient gender is
5. Pt.Enc.Past.Count - Patient has had a or more times in the past
6.
7. Pt.Proc.Past - Patient has had a
8.
9. Pt.Proc.Past.Lat - Patient has had a with a laterality of
10.
11. Pt.Proc.Past.Count - Patient has had a or more times in the past
12.
































THEN

1. Assert that

(show options...)


Web-Based Authoring – Decision Table

+ Decision table

	#	Desc	Vaccine	Gender	Dose #	Min Age	Units1	Max Age	Units2	Index Dose #	Min Interval	Units3	Rec Interval	Units4
 	1		 HPV	 Female	1	 9	 Yr	 26	 Yr					
 	2				2					1	24	 Day	61	 Day
 	3				 3					2	80		121	
 	4									1	164		182	
 	5			 Male	1	 11								
 	6				2					1	24	 Day	61	 Day
 	7				 3					2	80		121	
 	8									1	164		182	



Web-Based Authoring – Decision Diagram



OpenCDS Status

- 1.0 release scheduled December 2011
- Multiple ongoing initiatives within University of Utah and partner organizations



Recommendations

- Make CDS a core component of the PM vision
- Consider and prioritize **scalability** for CDS
- Leverage **relevant resources**
 - OpenCDS
 - Multiple CDS efforts focused on “traditional” medicine
- Align with, and influence, EHR **Meaningful Use** regulations
- Start building national CDS infrastructure **now**
 - Divergent, incompatible approaches will develop without coordination and standardization



Acknowledgements

- Financial support
 - NHGRI K01 HG004645 (PI: K. Kawamoto)
 - University of Utah Dept. of Biomedical Informatics
 - ONC Beacon Community Program subcontract (PI: Bruce Bray)
- Numerous OpenCDS collaborators
 - <https://sites.google.com/site/opencdspublic/collaborators>



Home



What is OpenCDS?

OpenCDS is a **multi-institutional, collaborative effort** to develop **open-source, standards-based clinical decision support (CDS) tools and resources** that can be widely adopted to enable CDS at scale.

Who is Involved?

OpenCDS was founded by Dr. Kensaku Kawamoto, MD, PhD, who is a faculty member at the Duke Center for Health Informatics and a co-chair of the HL7 CDS Work Group. OpenCDS collaborators include the University of Utah, Intermountain Healthcare, the Veterans Health Administration, the University of North Carolina at Chapel Hill, and Apelon, Inc.

Breaking News

[OpenCDS Alpha Release Available](#) An alpha release of OpenCDS is now available to collaborators. Please see the Alpha Release tab for more information.

Posted Apr 26, 2011 9:51 AM by Kensaku Kawamoto

[EBSCO Joins as OpenCDS Collaborator](#) The OpenCDS team is very excited to announce that EBSCO, one of the leading knowledge content providers in healthcare, has joined OpenCDS as a collaborator. The OpenCDS team will be ...

Posted Apr 26, 2011 9:51 AM by Kensaku Kawamoto

[OpenCDS at AMIA 2010](#) OpenCDS collaborators will be discussing OpenCDS and/or its component technologies at the following sessions of the 2010 American Medical Informatics Association (AMIA) Fall Symposium, which will be held in ...

Posted Apr 26, 2011 9:50 AM by Kensaku Kawamoto

Thank You!

Kensaku Kawamoto, MD, PhD

Director, Knowledge Management and Mobilization
Assistant Professor, Department of Biomedical Informatics
University of Utah

kensaku.kawamoto@utah.edu

